Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis
Mohamad Jawhar, Juliana Schwaab, Iván Álvarez‐Twöse, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 31, pp. 2846-2856
Open Access | Times Cited: 103

Showing 1-25 of 103 citing articles:

Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal
Peter Valent, Cem Akin, Karin Hartmann, et al.
HemaSphere (2021) Vol. 5, Iss. 11, pp. e646-e646
Open Access | Times Cited: 204
Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management
Animesh Pardanani
American Journal of Hematology (2021) Vol. 96, Iss. 4, pp. 508-525
Open Access | Times Cited: 142
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial
Daniel J. DeAngelo, Deepti Radia, Tracy I. George, et al.
Nature Medicine (2021) Vol. 27, Iss. 12, pp. 2183-2191
Open Access | Times Cited: 106
Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management
Animesh Pardanani
American Journal of Hematology (2023) Vol. 98, Iss. 7, pp. 1097-1116
Open Access | Times Cited: 60
Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis
Georg Greiner, Bettina Sprinzl, Aleksandra Górska, et al.
Blood (2020) Vol. 137, Iss. 2, pp. 238-247
Open Access | Times Cited: 137
New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis
Andreas Reiter, Tracy I. George, Jason Gotlib
Blood (2020) Vol. 135, Iss. 16, pp. 1365-1376
Open Access | Times Cited: 112
Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User’s Guide for Daily Clinical Practice
Peter Valent, Karin Hartmann, Juliana Schwaab, et al.
The Journal of Allergy and Clinical Immunology In Practice (2022) Vol. 10, Iss. 8, pp. 1999-2012.e6
Open Access | Times Cited: 47
New Insights into the Pathogenesis of Mastocytosis: Emerging Concepts in Diagnosis and Therapy
Peter Valent, Cem Akin, Wolfgang R. Sperr, et al.
Annual Review of Pathology Mechanisms of Disease (2022) Vol. 18, Iss. 1, pp. 361-386
Open Access | Times Cited: 41
Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study
Javier I. Muñoz‐González, Iván Álvarez‐Twöse, María Jara‐Acevedo, et al.
The Lancet Haematology (2021) Vol. 8, Iss. 3, pp. e194-e204
Closed Access | Times Cited: 51
Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group
Gregor Hoermann, Karl Sotlar, Mohamad Jawhar, et al.
The Journal of Allergy and Clinical Immunology In Practice (2022) Vol. 10, Iss. 8, pp. 1953-1963
Open Access | Times Cited: 37
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis
Andreas Reiter, Jason Gotlib, Iván Álvarez‐Twöse, et al.
Leukemia (2022) Vol. 36, Iss. 8, pp. 2108-2120
Open Access | Times Cited: 35
Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis
Johannes Lübke, Juliana Schwaab, Nicole Naumann, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 16, pp. 1783-1794
Open Access | Times Cited: 33
The international consensus classification of mastocytosis and related entities
Roos J. Leguit, Sa A. Wang, Tracy I. George, et al.
Virchows Archiv (2022) Vol. 482, Iss. 1, pp. 99-112
Closed Access | Times Cited: 32
Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis
Andreas Reiter, Juliana Schwaab, Daniel J. DeAngelo, et al.
Blood Advances (2022) Vol. 6, Iss. 21, pp. 5750-5762
Open Access | Times Cited: 29
Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry
Vanessa E. Kennedy, Cecelia Perkins, Andreas Reiter, et al.
Blood Advances (2022) Vol. 7, Iss. 9, pp. 1713-1724
Open Access | Times Cited: 28
Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis
Roberta Zanotti, Massimiliano Bonifacio, Giuseppe Lucchini, et al.
Leukemia (2021) Vol. 36, Iss. 2, pp. 516-524
Open Access | Times Cited: 40
Avapritinib for advanced systemic mastocytosis
Jason Gotlib, Andreas Reiter, Daniel J. DeAngelo
Blood (2022) Vol. 140, Iss. 15, pp. 1667-1673
Closed Access | Times Cited: 27
Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022
Michel Arock, Gregor Hoermann, Karl Sotlar, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 149, Iss. 6, pp. 1855-1865
Open Access | Times Cited: 26
Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries
Johannes Lübke, Deborah Christen, Juliana Schwaab, et al.
Leukemia (2024) Vol. 38, Iss. 4, pp. 810-821
Open Access | Times Cited: 5
Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee
Donal P. McLornan, Tomasz Czerw, Gandhi Damaj, et al.
Leukemia (2024)
Closed Access | Times Cited: 5
Importance of Adequate Diagnostic Workup for Correct Diagnosis of Advanced Systemic Mastocytosis
Juliana Schwaab, Nicole Cabral do O Hartmann, Nicole Naumann, et al.
The Journal of Allergy and Clinical Immunology In Practice (2020) Vol. 8, Iss. 9, pp. 3121-3127.e1
Open Access | Times Cited: 39
Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis
Hanneke C. Kluin‐Nelemans, Mohamad Jawhar, Andreas Reiter, et al.
Theranostics (2020) Vol. 11, Iss. 1, pp. 292-303
Open Access | Times Cited: 33
Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis
Bogusław Nedoszytko, Michel Arock, Jonathan J. Lyons, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 1, pp. 411-411
Open Access | Times Cited: 27
Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms
Jason Gotlib
Hematology (2022) Vol. 2022, Iss. 1, pp. 34-46
Open Access | Times Cited: 20
World Health Organization Classification and Diagnosis of Mastocytosis
Peter Valent, Karl Sotlar, Hans‐Peter Horny, et al.
Immunology and Allergy Clinics of North America (2023) Vol. 43, Iss. 4, pp. 627-649
Closed Access | Times Cited: 11
Page 1 - Next Page

Scroll to top